IMRX
Immuneering Corporation
$3.73
-2.10%
2026-10-23
About Immuneering Corporation
Immuneering Corporation, a late-stage oncology company, develops medicines for broad populations of cancer patients in the United States. The company develops IMM-1-104 (atebimetinib), a dual-MEK inhibitor that is in a Phase 3 clinical trial to treat patients with cancer, including pancreatic and non-small cell lung cancer caused by mutations of RAS or RAF; IMM-6-415 (envometinib), which is in Phase 1/2a clinical trial for the treatment of patients with solid tumors; and multiple deep cyclic inhibitor discovery programs. The company has clinical supply agreements with Regeneron Pharmaceuticals to evaluate atebimetinib in combination with Libtayo in patients with unresectable or metastatic RAS-mutant non-small cell lung cancer; and with Eli Lilly and Company to evaluate atebimetinib in combination with olomorasib in patients with advanced or metastatic KRAS G12C-mutant non-small cell lung cancer. Immuneering Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.
Key Fundamentals
Forward P/E
-3.40
EPS (TTM)
$-0.93
ROE
-52.1%
Profit Margin
0.0%
Debt/Equity
1.91
Price/Book
1.45
Beta
0.39
Market Cap
$276.3M
Avg Volume (10D)
708K
Recent Breakout Signals
Recent Price Range (60 Days)
60D High
$5.43
60D Low
$3.38
Avg Volume
692K
Latest Close
$3.73
Get breakout alerts for IMRX
Sign up for Breakout Scanner to receive daily notifications when IMRX triggers breakout signals. Build custom AI screeners and backtest strategies.
Create your account7-day free trial, no card needed. Then $20/month.
Immuneering Corporation (IMRX) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors IMRX daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. IMRX operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.